Supplemental material
Expert Opinion on Drug Safety
Volume 22, 2023 - Issue 2
Original Research
Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study
Nobuya Inagakia Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
https://orcid.org/0000-0001-8261-2593View further author information
https://orcid.org/0000-0001-8261-2593View further author information, Takaaki Nishimotob Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K, Kobe, JapanCorrespondence[email protected]
https://orcid.org/0000-0003-0837-2231View further author information
https://orcid.org/0000-0003-0837-2231View further author information, Yoichi Nishiyac Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0000-0003-0063-9982View further author information
https://orcid.org/0000-0003-0063-9982View further author information & Daisuke Nittac Medicine Division, Nippon Boehringer Ingelheim Co. Ltd, Tokyo, Japanhttps://orcid.org/0000-0001-5881-1533View further author information
https://orcid.org/0000-0001-5881-1533View further author information